latest news releases from the newsroom
Hemispherx Biopharma, Inc.
Hemispherx Biopharma Addresses FDA Questions On Ampligen NDA
PHILADELPHIA, Jan. 9, 2008 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) announced today that it has formally submitted to the United States Food & Drug Administration ("FDA") detailed responses to all of the 14 questions posed by the FDA concerning the Company's New Drug Application ("NDA") for Ampligen(r), an experimental therapeutic, to treat Chronic Fatigue Syndrome ("CFS"). Hemispherx received the questions from the FDA on December 5, 2007, at which point the application was deemed by the FDA as "not sufficiently complete" to permit substantive review under 21 CFR 314.101(R). Consequently, the FDA's consideration of the NDA was postponed, pending receipt of the Company's answers to the questions.
PSS World Medical to Broadcast Its Fiscal 2008 Third Quarter Conference Call Live On the Internet
JACKSONVILLE, Fla., Jan. 9, 2008 (PRIME NEWSWIRE) -- PSS World Medical, Inc. (Nasdaq:PSSI) today announced that it will provide an online Web simulcast of its fiscal 2008 third quarter conference call on Thursday, January 24, 2008. The Company's financial results for the third quarter and nine months ended December 28, 2007, will be released after the close of market trading on Wednesday, January 23, 2008.
Parallels Server Beta Available for Windows, Linux and Mac OS X Powered Servers
RENTON, Wash., Jan. 9, 2008 (PRIME NEWSWIRE) -- SWsoft (soon to be renamed Parallels) today announced the release of the beta version of Parallels Server, the company's hypervisor-powered server virtualization solution. Parallels Server is the first virtualization solution designed to run on Apple hardware, including Mac Pros and Xserves, and the first to run multiple copies of Mac OS X Server v10.5 Leopard on a single Apple computer. Parallels Server also runs on any x86 or 64-bit Windows or Linux-based server.